Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
- DOI
- 10.1016/j.jtho.2023.09.1445
- Published
- 2024 Feb
- Container
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtho.2023.09.1445,
title = {Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.},
author = {Reck M and Barlesi F and Yang JC and Westeel V and Felip E and Özgüroğlu M and Dols MC and Sullivan R and Kowalski DM and Andric Z and Lee DH and Sezer A and Hu P and Wang X and von Heydebreck A and Jacob N and Mehr KT and Park K},
year = {2024},
journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
doi = {10.1016/j.jtho.2023.09.1445},
url = {https://doi.org/10.1016/j.jtho.2023.09.1445}
}RIS
TY - JOUR TI - Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial. AU - Reck M AU - Barlesi F AU - Yang JC AU - Westeel V AU - Felip E AU - Özgüroğlu M AU - Dols MC AU - Sullivan R AU - Kowalski DM AU - Andric Z AU - Lee DH AU - Sezer A AU - Hu P AU - Wang X AU - von Heydebreck A AU - Jacob N AU - Mehr KT AU - Park K PY - 2024 JO - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer DO - 10.1016/j.jtho.2023.09.1445 UR - https://doi.org/10.1016/j.jtho.2023.09.1445 ER -
APA
M, R., F, B., JC, Y., V, W., E, F., M, Ö., MC, D., R, S., DM, K., Z, A., DH, L., A, S., P, H., X, W., A, V. H., N, J., KT, M., & K, P. (2024). Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2023.09.1445
Source records
- pubmed · retrieved 2026-09-25T23:47:03.995Z